about
Catch me if you can: Leukemia Escape after CD19-Directed T Cell ImmunotherapiesIntegrative network and transcriptomics-based approach predicts genotype- specific drug combinations for melanoma.Combinatorial Therapies in Melanoma: MAPK Inhibitors and Beyond.Somatic driver mutations in melanoma.Combinatorial immunotherapy for melanoma.Targeting protein kinase-b3 (akt3) signaling in melanoma.Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours.Combinations of targeted therapies in human cancers.Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase lb study.BRAF inhibitors: resistance and the promise of combination treatments for melanoma.DNA methylation/hydroxymethylation in melanoma.The anti-apoptotic BAG3 protein is involved in BRAF inhibitor resistance in melanoma cells.Potassium Ascorbate with Ribose: Promising Therapeutic Approach for Melanoma Treatment.Efficacy of Vemurafenib Treatment in 43 Metastatic Melanoma Patients with BRAF Mutation. Single-Institute Retrospective Analysis, Early Real-Life Survival Data.Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine.p53 loss does not permit escape from BrafV600E-induced senescence in a mouse model of lung cancer.Perioperative BRAF inhibitors in locally advanced stage III melanoma.Targeting melanoma stem cells with the Vitamin E derivative δ-tocotrienol.Clinical evaluation of macrophages in cancer: role in treatment, modulation and challenges.New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging.18F-FDG-PET/CT and diffusion-weighted MRI for monitoring a BRAF and CDK 4/6 inhibitor combination therapy in a murine model of human melanoma.Combining molecular and immunohistochemical analyses of key drivers in primary melanomas: interplay between germline and somatic variations.Methotrexate sensitizes drug-resistant metastatic melanoma cells to BRAF V600E inhibitors dabrafenib and encorafenib.Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs' Revolution for Immunotherapy.BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers.BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report.Microenvironment-Driven Dynamic Heterogeneity and Phenotypic Plasticity as a Mechanism of Melanoma Therapy Resistance.BRAF inhibitors stimulate inflammasome activation and interleukin 1 beta production in dendritic cells.Melanoma Cell Death MechanismsWhole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A
P2860
Q28072131-81ED0085-EB4F-4DE7-A599-2FE89867C0C8Q38621140-BA7675DC-C7C9-4826-BC60-2845633BA3B0Q38634557-9B45DFE8-2DD2-45AA-BAF0-F552911E1940Q38764368-ED4C6F0D-D040-407E-A6FE-5E8FE76B093FQ39005199-7B35F594-C9E9-494A-9EDF-A4CB9EDB84C5Q39074281-DDE9784B-88BB-49DE-9372-7D68E3F197D1Q40240418-B8420418-2440-41A3-B361-A40BB0EDE7FFQ42082875-5E4E1680-B920-46A6-BF0B-B8C9311D683EQ46071137-65146E20-D0F1-4CE9-A76D-FA117C66599EQ47104481-40A273DB-88D0-4994-8042-7906D112A0A0Q47119104-ACF34068-A8F9-4AE3-8CA3-3D4B272CD655Q47139368-561FB03C-BB21-4703-BB09-AA09D3C92944Q47151869-F5A73652-CD4C-4E10-B9A0-1AEEDC3F2331Q47256456-5A11D43C-16C6-438E-A0B8-71606A12A527Q47392574-D6E11FCC-9FD2-4C14-B731-53A2B8BDE879Q48026380-D0C5C1B6-E860-4671-8DB2-7003416A3913Q48222490-27D46B31-84D8-482C-B12E-89904CD31DBFQ48251370-753EC565-413B-4EE1-B81E-28A4C9622BEAQ48290538-87BFC56D-09B8-4C35-8D89-B74BCAAA7C32Q48588744-AF9C544A-39D1-4ADF-B3C9-9F24C70E2457Q49770136-82C36807-459E-4FCB-A1E3-AE4BEF380EDBQ49787884-852858AB-9701-4CB1-ACF5-D7D67F810122Q52641587-522B37E0-A789-4E90-B1C4-18EA64F4EA5BQ52657766-874833E8-6570-4F17-9F91-4DFF747E623EQ53705974-8252C3BF-9AD1-45B8-A0A9-60F03FF9869FQ55090775-159C0241-4B6B-414A-87E5-B831C3490F25Q55424318-FF3CADEB-0FF7-4568-B701-B0352086A56BQ55467257-4D8F58E2-6D9F-4E70-AA28-258D10F40F8CQ57120881-C2446000-9FD0-47E1-99CF-846964C13AB9Q58766034-AEEB754B-299A-4561-B915-B78782B5F883
P2860
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
name
Resistant mechanisms to BRAF inhibitors in melanoma
@ast
Resistant mechanisms to BRAF inhibitors in melanoma
@en
Resistant mechanisms to BRAF inhibitors in melanoma
@nl
type
label
Resistant mechanisms to BRAF inhibitors in melanoma
@ast
Resistant mechanisms to BRAF inhibitors in melanoma
@en
Resistant mechanisms to BRAF inhibitors in melanoma
@nl
prefLabel
Resistant mechanisms to BRAF inhibitors in melanoma
@ast
Resistant mechanisms to BRAF inhibitors in melanoma
@en
Resistant mechanisms to BRAF inhibitors in melanoma
@nl
P2093
P2860
P3181
P356
P1476
Resistant mechanisms to BRAF inhibitors in melanoma
@en
P2093
Cristina Bugés
Eva Martínez-Balibrea
José Luís Manzano
Laura Layos
María de Los Llanos Gil
P2860
P3181
P356
10.21037/ATM.2016.06.07
P407
P577
2016-06-01T00:00:00Z